CompletedNCT06299319
Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant OCD
This study evaluated the safety of Psilocybin for people with OCD.
Medication studyAges 18–65Canada
Understand this study
What did researchers investigate?
This study evaluated the safety of Psilocybin for people with OCD.
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- TorontoSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateStarted: September 1, 2024
- Recruitment status
- Completed
- Enrollment listed in the registry
- 10
- Sponsor
- Centre for Addiction and Mental Health
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- Canada
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT06299319
- Official title
Show the full official title
Evaluating the Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant Obsessive-compulsive Disorder: An Open-label Clinical Trial
Recruitment & locations
CompletedToronto
Questions about this study
What did researchers investigate?
This study evaluated the safety of Psilocybin for people with OCD.
Who is behind this study?
The study sponsor is Centre for Addiction and Mental Health, a hospital or academic medical center.
Did this study involve medication?
Yes. The study involved medication, including Psilocybin.
Who was this study for?
Listed age limits: 18 years to 65 years.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit me